Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination
Targeting the glycolytic PFKFB3 enzyme is being studied as a therapeutic strategy against cancer. Here the authors identify PFKFB3 as being involved in homologous recombination (HR) repair of DNA double strand breaks (DSBs) and present a PFKFB3 inhibitor.
Main Authors: | Nina M. S. Gustafsson, Katarina Färnegårdh, Nadilly Bonagas, Anna Huguet Ninou, Petra Groth, Elisee Wiita, Mattias Jönsson, Kenth Hallberg, Jemina Lehto, Rosa Pennisi, Jessica Martinsson, Carina Norström, Jessica Hollers, Johan Schultz, Martin Andersson, Natalia Markova, Petra Marttila, Baek Kim, Martin Norin, Thomas Olin, Thomas Helleday |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-09-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-06287-x |
Similar Items
-
PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair
by: Anna Huguet Ninou, et al.
Published: (2021-07-01) -
Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum
by: Jemina Lehto, et al.
Published: (2021-03-01) -
Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets
by: Krzysztof Kotowski, et al.
Published: (2021-02-01) -
The metabolic role of PFKFB4 in androgen-independent growth in vitro and PFKFB4 expression in human prostate cancer tissue
by: Ximing Li, et al.
Published: (2020-06-01) -
Insights into the Development of Chemotherapeutics Targeting PFKFB Enzymes
by: Crochet, Robert Blake
Published: (2015)